Long term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas: a monocentric analysis.
Giovanni RindoneAndrea AroldiElisa BossiLuisa VergaGiovanni Paolo Maria ZambrottaSara TarantinoRocco Giovanni PiazzaLara MussolinRoberto ChiarleCarlo B Gambacorti-PasseriniPublished in: Blood advances (2022)